TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of restricted stock units (RSUs) covering 6,600 shares of common stock, awarded to twelve newly-hired employees with a grant date of May 5, 2025. These RSUs, granted under Nasdaq Rule 5635(c)(4), will vest in equal annual installments over a four-year period, contingent on continued employment with TELA Bio.
TELA Bio (NASDAQ: TELA), un'azienda di tecnologia medica specializzata in soluzioni per la ricostruzione dei tessuti molli, ha annunciato l'approvazione di concessioni di incentivi da parte del Comitato per la Remunerazione del suo Consiglio di Amministrazione. Le concessioni consistono in unità di azioni vincolate (RSU) che coprono 6.600 azioni ordinarie, assegnate a dodici nuovi dipendenti con data di assegnazione il 5 maggio 2025. Queste RSU, concesse ai sensi della Regola Nasdaq 5635(c)(4), matureranno in quote annuali uguali per un periodo di quattro anni, a condizione che il rapporto di lavoro con TELA Bio continui.
TELA Bio (NASDAQ: TELA), una empresa de tecnología médica especializada en soluciones para la reconstrucción de tejidos blandos, ha anunciado la aprobación de concesiones por incentivos por parte del Comité de Compensación de su Junta Directiva. Las concesiones consisten en unidades de acciones restringidas (RSU) que cubren 6,600 acciones comunes, otorgadas a doce empleados recién contratados con fecha de concesión del 5 de mayo de 2025. Estas RSU, otorgadas bajo la Regla Nasdaq 5635(c)(4), se consolidarán en cuotas anuales iguales durante un período de cuatro años, condicionado a la continuidad del empleo en TELA Bio.
TELA Bio (NASDAQ: TELA)는 연조직 재건 솔루션을 전문으로 하는 의료 기술 회사로, 이사회의 보상 위원회가 유인 보조금 승인을 발표했습니다. 이 보조금은 6,600주의 보통주에 해당하는 제한 주식 단위(RSU)로 구성되며, 12명의 신입 직원에게 2025년 5월 5일 부여일로 수여됩니다. 이 RSU는 Nasdaq 규칙 5635(c)(4)에 따라 부여되며, TELA Bio에서 계속 근무하는 조건으로 4년 기간 동안 매년 동일한 비율로 취득됩니다.
TELA Bio (NASDAQ : TELA), une entreprise de technologie médicale spécialisée dans les solutions de reconstruction des tissus mous, a annoncé l'approbation des subventions d'incitation par le comité de rémunération de son conseil d'administration. Ces subventions consistent en des unités d'actions restreintes (RSU) couvrant 6 600 actions ordinaires, attribuées à douze nouveaux employés avec une date d'attribution fixée au 5 mai 2025. Ces RSU, accordées conformément à la règle Nasdaq 5635(c)(4), seront acquises par tranches annuelles égales sur une période de quatre ans, sous réserve de la poursuite de l'emploi chez TELA Bio.
TELA Bio (NASDAQ: TELA), ein Medizintechnikunternehmen, das sich auf Lösungen zur Weichgeweberekonstruktion spezialisiert hat, gab die Genehmigung von Anreizzuteilungen durch den Vergütungsausschuss des Vorstands bekannt. Die Zuteilungen bestehen aus Restricted Stock Units (RSUs) über 6.600 Aktien des Stammkapitals, die an zwölf neu eingestellte Mitarbeiter mit einem Zuteilungsdatum vom 5. Mai 2025 vergeben werden. Diese RSUs, die gemäß Nasdaq-Regel 5635(c)(4) gewährt werden, werden über einen Vierjahreszeitraum in gleichen jährlichen Raten unverfallbar, vorausgesetzt, die Beschäftigung bei TELA Bio wird fortgesetzt.
- None.
- None.
MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
What type of inducement grants did TELA Bio (TELA) announce in May 2025?
How will the TELA Bio (TELA) RSU inducement grants vest?
How many employees received TELA Bio (TELA) inducement grants in May 2025?
Under which Nasdaq rule were TELA Bio's (TELA) inducement grants awarded?
